# Pearl Diagnostics

> Johns Hopkins spinout commercializing noninvasive urine assays for lung infections (Aspergillus, Pseudomonas).

## Why it is interesting

Rare Baltimore diagnostics commercialization: FDA 510(k) clearance for MycoMEIA Aspergillus assay (Aug 2025) plus $11.2M Series A (Mar 2026, SEC filing) to launch U.S. sales — EV-based lung infection detection, not another generic PCR panel.

## Profile

- **Stage:** series-a
- **Status:** private
- **Industries:** biotech-life-sciences, healthtech
- **Coverage:** full
- **Last updated:** 2026-07-29

## Key facts

- Johns Hopkins spinout (2014); HQ Baltimore
- FDA 510(k) clearance: MycoMEIA Aspergillus assay (Aug 2025)
- Series A (Mar 2026): $11.2M per SEC filing (Technical.ly coverage)
- CEO Eric Gornstein joined for commercialization push

## Related articles

- https://venturecapitaltracker.com/baltimore-startups-and-vc-firms-2026

---
Source: https://venturecapitaltracker.com/startup/pearl-diagnostics